If this is not your name, click here.
| | If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| |  Adalimumab Benefits Broad Span of Psoriasis Patients: Presented at AAD By Jill Stein SAN FRANCISCO -- March 11, 2009 -- Adalimumab treatment confers consistent benefits in psoriasis patients regardless of different disease and treatment histories, according to patient-reported outcomes data presented here at the American Academy of Dermatology (AAD) 67th Annual Meeting. Alexa Kimball, MD, Harvard Medical School, Boston, Massachusetts, and colleagues reported data from 2 phase 3 trials of 1,362 patients with moderate to severe psoriasis. They presented their findings on March 9. "The efficacy of adalimumab versus placebo for patients with moderate to severe psoriasis has been widely documented in terms of reducing physician-assessed psoriasis symptoms and improving patient-reported outcomes," Dr. Kimball noted. "Candidates for adalimumab may have different disease and treatment histories," she said. "Adalimumab has been shown to have consistent effects in physician-assessed psoriasis symptoms across various subgroups of patients." To examine whether the benefits of adalimumab on patient-reported outcomes are consistent across subgroups of patients with different disease histories, Dr. Kimball and colleagues evaluated patients randomised to adalimumab 40 mg every other week after an 80 mg induction dose or placebo. They evaluated various measures at baseline and then at 16 weeks or at early termination, including the Dermatology Life Quality Index (DLQI), the Work Productivity and Activity Impairment (WPAI) questionnaire, and the Short Form 36 Health Survey (SF-36) Physical and Mental Component Summary (PCS and MCS, respectively). Patients were stratified into subgroups by age (<40 or >=40 years), duration of psoriasis (>16 years or <=16 years), prior exposure to any systemic therapy, and prior exposure to nonbiological systemic therapies. Results showed that the adalimumab cohort had significantly larger health-related quality of life improvements than placebo patients (P < .01), ranging from 6.0 to 7.2 units across subgroups for DLQI, 1.9 to 4.7 units for SF-36 MCS, 2.9 to 4.7 units for SF-36 PCS, and 9.4 to 13.6 units for WPAI. In addition, younger patients and patients with shorter disease duration experienced larger improvements in patient-reported outcomes with adalimumab therapy than did older patients or those with longer disease duration. Dr. Kimball cautioned that "some subgroups, particularly those defined by response to prior treatment, included small numbers of patients and provided imprecise estimates of the effect of adalimumab versus placebo." Funding for this study was provided by Abbott.
[Presentation title: Adalimumab's Benefits for Patient-Reported Outcomes in Psoriasis Patients Are Consistent Across Subgroups With Different Disease Histories. Abstract P3391]
|
